KR20230005808A - 골수섬유증의 치료를 위한 화합물 - Google Patents

골수섬유증의 치료를 위한 화합물 Download PDF

Info

Publication number
KR20230005808A
KR20230005808A KR1020227025801A KR20227025801A KR20230005808A KR 20230005808 A KR20230005808 A KR 20230005808A KR 1020227025801 A KR1020227025801 A KR 1020227025801A KR 20227025801 A KR20227025801 A KR 20227025801A KR 20230005808 A KR20230005808 A KR 20230005808A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
administered
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227025801A
Other languages
English (en)
Korean (ko)
Inventor
프란시스 제이. 질스
앤드류 마자르
Original Assignee
액투에이트 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액투에이트 테라퓨틱스 인크. filed Critical 액투에이트 테라퓨틱스 인크.
Publication of KR20230005808A publication Critical patent/KR20230005808A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227025801A 2019-12-26 2020-12-23 골수섬유증의 치료를 위한 화합물 Withdrawn KR20230005808A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953654P 2019-12-26 2019-12-26
US62/953,654 2019-12-26
PCT/US2020/066762 WO2021133866A1 (en) 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis

Publications (1)

Publication Number Publication Date
KR20230005808A true KR20230005808A (ko) 2023-01-10

Family

ID=74186982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025801A Withdrawn KR20230005808A (ko) 2019-12-26 2020-12-23 골수섬유증의 치료를 위한 화합물

Country Status (11)

Country Link
US (1) US20230062278A1 (https=)
EP (1) EP4081213A1 (https=)
JP (1) JP2023508491A (https=)
KR (1) KR20230005808A (https=)
CN (1) CN115697323A (https=)
AU (1) AU2020415440A1 (https=)
BR (1) BR112022012819A2 (https=)
CA (1) CA3166251A1 (https=)
IL (1) IL294369A (https=)
MX (1) MX2022008046A (https=)
WO (1) WO2021133866A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) * 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
CN113384546A (zh) * 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
CN112351819B (zh) * 2018-06-05 2023-11-10 开动疗法公司 治疗恶性淋巴增生性疾病的方法

Also Published As

Publication number Publication date
CN115697323A (zh) 2023-02-03
BR112022012819A2 (pt) 2022-09-06
CA3166251A1 (en) 2021-07-01
IL294369A (en) 2022-08-01
JP2023508491A (ja) 2023-03-02
MX2022008046A (es) 2022-11-14
WO2021133866A1 (en) 2021-07-01
EP4081213A1 (en) 2022-11-02
US20230062278A1 (en) 2023-03-02
AU2020415440A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
Frei et al. High dose methotrexate with leucovorin rescue: rationale and spectrum of antitumor activity
Loh et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
EP2675451B1 (en) mTOR/JAK INHIBITOR COMBINATION THERAPY
Britten et al. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
UA125216C2 (uk) Комбінована терапія
EP2986299B1 (en) 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for treating glioblastoma multiforme
D’Cruz et al. Novel Bruton’s tyrosine kinase inhibitors currently in development
Zhang et al. Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia
Carlo-Stella et al. A first-in-human study of tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: results from the European study
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
Rui et al. The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis
JP2022502492A (ja) 骨髄増殖性疾患の治療法
Iida et al. A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma
Gotesman et al. mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
Goulart et al. A phase I/II trial of ruxolitinib with chemotherapy for patients with relapsed and/or refractory Philadelphia-like acute lymphoblastic leukemia
CN120202005A (zh) 使用选择性雌激素受体降解剂（serd）治疗乳腺癌的方法
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
KR102505218B1 (ko) BCL-2 억제제와 MCl-1 억제제의 조합물, 이의 용도 및 약학적 조성물
KR20230005808A (ko) 골수섬유증의 치료를 위한 화합물
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
Dudek et al. 717TiP An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
US20240058343A1 (en) Treatment of urticaria using jak inhibitors
TW202521118A (zh) 治療alk陽性或ros1陽性的非小細胞肺癌的方法
US20230090742A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220725

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20241120

WITB Written withdrawal of application